Sort
10,766 grants matching “checkpoint inhibitor”
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2023 · GM
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$562,792Miguel Angel Villalona · University Of California-Irvine · R01 · FY2025 · CA
RNA editing in islet function and inflammation
$562,668Alvin Carter Powers · Vanderbilt University Medical Center · R01 · FY2023 · DK
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy
$562,597Jin-Ming Yang · University Of Kentucky · R01 · FY2020 · CA
Targeting myeloid suppression to enhance anti-tumor immunity in breast cancer
$562,338Evanthia Theodosiou Roussos Torres · University Of Southern California · R01 · FY2025 · CA
Studies of Materials with Physiological Properties
$562,258Harvard University · R01 · FY2005 · GM
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$561,956Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2023 · CA
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
$561,945Jing Hong Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · DE
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy
$561,881Jin-Ming Yang · University Of Kentucky · R01 · FY2021 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells
$561,734David G Denardo · Washington University · R01 · FY2024 · CA
Regulation of Mitotic Kinetochores by the Ran GTPase
$561,667Mary C. Dasso · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · Z01 · FY2008 · HD
Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma
$561,558Peter Karl Sorger · Harvard Medical School · U54 · FY2019 · CA
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$561,402Alfred Ayala · Rhode Island Hospital · R35 · FY2021 · GM
Modulation of the tumor microenvironment with probiotic therapies
$561,341Tal Danino · Columbia Univ New York Morningside · R01 · FY2022 · CA
Tumor Immune MicroEnvironment Facility (Scientific Core)
$561,301Wiem Lassoued · Division Of Basic Sciences - Nci · ZIC · FY2024 · CA
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
$561,099Efstathios Karathanasis · Case Western Reserve University · R01 · FY2024 · CA
Multiscale analysis of metabolic inflammation as a driver of breast cancer
$560,974Gerald V Denis · Boston University Medical Campus · U01 · FY2021 · CA
Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer Immunotherapy
$560,955Hai-Quan Mao · Johns Hopkins University · R01 · FY2023 · CA
Molecular Regulation of B cells and T cells in Human SLE
$560,943Ignacio E. Sanz · Emory University · U19 · FY2021 · AI
Project-002
$560,943Ignacio E. Sanz · Emory University · U19 · FY2021 · AI
Metabolic regulators of Treg/Th17 balance in CNS autoimmunity
$560,922Vijay K Kuchroo · Brigham And Women'S Hospital · R01 · FY2022 · AI
Molecular, Cellular and Genetic Analyses of Malignancies Associated with NF1
$560,920Karlyne M Reilly · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Escape from CAR T surveillance through lineage plasticity
$560,773Patricia A Ernst · University Of Colorado Denver · R01 · FY2023 · CA
Targeting adrenergic stress pathways to Increase tumor sensitivity to radiation and promote development of an anti-tumor immune response
$560,552Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA
Targeting adrenergic stress pathways to Increase tumor sensitivity to radiation and promote development of an anti-tumor immune response
$560,552Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA